Sara Hedfors Vidlin

Uppsala Monitoring Centre · Research

IntroductionThe safety profile of remdesivir, conditionally approved for COVID-19, was limited at its 2020 introduction. Adverse drug reactions (ADRs) for medicines are collected in VigiBase, the WHO Global Database of Individual Case Safety Reports (ICSRs).Objective This study aimed to provide a descriptive analysis of COVID-19 ICSR data focusing...

Introduction: In late 2019, a new coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-was discovered in Wuhan, China, and the World Health Organization later declared coronavirus disease 2019 (COVID-19) a pandemic. Numerous drugs have been repurposed and investigated for therapeutic effectiveness in the disease, including thos...

IntroductionAdverse drug reactions related to drug–drug interactions cause harm to patients. There is a body of research on signal detection for drug interactions in collections of individual case reports, but limited use in regular pharmacovigilance.Objective The aim of this study was to evaluate the feasibility of signal detection of drug–drug in...

IntroductionA large number of studies on systems to detect and sometimes normalize adverse events (AEs) in social media have been published, but evidence of their practical utility is scarce. This raises the question of the transferability of such systems to new settings.Objectives The aims of this study were to develop an AE recognition system, pr...